Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: A phase I study

Lung Cancer

Volumn 47, Issue 2, 2005, Pages 261-267

  Ibrahim, Toni ^a   Zoli, Wainer ^a   Frassineti, Giovanni Luca ^a   Tesei, Anna ^b   Colantonio, Ida ^c   Monti, Manuela ^b   Amadori, Dino ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Docetaxel; Gemcitabine; Phase I study; Preclinical data; Stage III IV NSCLC

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN CELL; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 11444256552     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.06.011     Document Type: Article

References (29)

1. W. Zoli, L. Ricotti, M. Dal Susino, F. Barzanti, G.L. Frassineti, and S. Folli Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer Br J Cancer 81 1999 609 615
2. G.L. Frassineti, T. Ibrahim, W. Zoli, M. Monti, L. Ricotti, and O. Nanni Docetaxel followed by gemcitabine in the treatment of advanced non-small cell lung cancer: a phase I study Tumori 88 2002 99 103
3. A. Gasperi-Campani, L. Roncuzzi, L. Ricotti, L. Lenzi, R. Gruppioni, and A. Sensi Molecular and biological features of two new human squamous and adenocarcinoma of the lung cell lines Cancer Genet Cytogenet 107 1998 11 20
4. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMohan, and D. Vistica New colorimetric cytotoxic assay for anticancer drug screening J Natl Cancer Inst 13 1990 1107 1112
5. B. Drewinko, T.L. Loo, B. Brown, J.A. Gottlieb, and E.J. Freireich Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells Cancer Biochem Biophys. 1 1976 187 195
6. M.G. Kendal, and A. Stuard The advanced theory of statistics, vol. 1, section 10.6, vol. II 1983 Hafner Publishing Company Inc. New York [chapters 17 and 18]
7. American Society of Clinical Oncology: recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.
8. P.J. Souquet, F. Chauvin, J.P. Boissel, R. Cellerino, Y. Cormier, and P.A. Ganz Polychemotherapy in advanced non small cell lung cancer: a meta-analysis Lancet 342 1993 19 21
9. Non Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br Med J 311 1995 899 909
10. J.H. Schiller Platin or no platin? That is the question J Clin Oncol. 21 2003 3009 3010
11. P.D. Bonomi, D.M. Finkelstein, J.C. Ruckdeschel, R.H. Blum, M.D. Green, and B. Mason Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group J Clin Oncol. 7 1989 1602 1613
12. J. Klastersky, J.P. Sculier, H. Lacroix, G. Dabouis, G. Bureau, and P. Libert A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861 J Clin Oncol. 8 1990 1556 1562
13. P. Zatloukal, L. Novakova, L. Petruzelka, M. Zemanova, V. Kolek, and I. Grygarkova Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial Proc Am Soc Clin Oncol 21 2002 307a [Abstract 1225]
14. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, and J. Krook Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med. 346 2002 92 98
15. S. Jelic, L. Mitrovic, D. Radosavljevic, E. Elezar, N. Babovic, and V. Kovcin Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study Lung Cancer 34 2001 1 13
16. R. Rosell, U. Gatzemeier, D.C. Betticher, U. Keppler, H.N. Macha, and R. Pirker Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann Oncol. 13 2002 1539 1549
17. V. Georgoulias, C. Kouroussis, N. Androulakis, S. Kakolyris, M.A. Dimopoulos, and E. Papadakis Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial J Clin Oncol. 17 1999 914 920
18. C.H. Spiridonidis, L.R. Laufman, L. Carman, T. Moore, S. Blair, and J. Jones Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial Ann Oncol. 12 2001 89 94
19. N.A. Rizvi, C.H. Spiridonis, T.H. Davis, P. Bhargava, J.L. Marshall, and W. Dahut Docetaxel and gemcitabine combinations in NSCLC Semin Oncol. 26 Suppl 6 1999 S27 S31 [discussion S41-2 (Review)]
20. S. Kakolyris, E. Papadakis, X. Tsiafaki, C. Kalofonos, A. Rapti, and M. Toubis Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer A multicenter phase II study Lung Cancer 32 2001 179 187
21. P. Rebattu, X. Quantin, C. Ardiet, J.F. Morere, M.R. Azarian, and M.P. Schuller-Lebeau Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer Lung Cancer 33 2001 277 287
22. V. Georgoulias, E. Papadakis, A. Alexopoulos, X. Tsiafaki, A. Rapti, and M. Veslemes Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial Lancet 357 2001 1478 1484
23. S. Kakolyris, X. Tsiafaki, A. Agelidou, J. Arapis, J. Boukovinas, and N. Samaras Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer Proc Am Soc Clin Oncol. 21 2002 296a [Abstract 1182]
24. J.Y. Douillard, J. Eckardt, and G.V. Scagliotti Challenging the platinum combinations in the chemotherapy of NSCLC Lung Cancer 38 Suppl 4 2002 21 28
25. G.J. Peters, A.M. Bergman, V.W. Ruiz van Haperen, G. Veerman, C.M. Kuiper, and B.J. Braakhuis Interaction between cisplatin and gemcitabine in vitro and in vivo Semin Oncol. 22 Suppl 11 1995 S72 S79
26. C.J. van Moorsel, J.R. Kroep, H.M. Pinedo, G. Veerman, D.A. Voorn, and P.E. Postmus Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors Ann Oncol. 10 1999 441 448
27. S.M. Hahn, J.E. Liebmann, J. Cook, J. Fisher, B. Godspiel, and D. Venzon Taxol in combination with doxorubicin or etoposide Possible antagonism in vitro Cancer 72 1993 2705 2711
28. C. Theodossiou, J.A. Cook, J. Fisher, D. Teague, J.E. Liebmann, and A. Russo Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines Int J Oncol. 12 1998 825 832
29. W. Zoli, L. Ricotti, F. Barzanti, M. Dal Susino, G.L. Frassineti, and C. Milandri Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines Int J Cancer 80 1999 413 416